‘Why do children with cerebral palsy discontinue therapy with botulinum toxin A?’

Abstract

Developmental Medicine & Child NeurologyVolume 48, Issue 4 p. 319-320 Free Access ‘Why do children with cerebral palsy discontinue therapy with botulinum toxin A?’ Michaela Linder-Lucht MD, Corresponding Author Michaela Linder-Lucht MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg University *Correspondence to: [email protected]Search for more papers by this authorJanbernd Kirschner MD, Janbernd Kirschner MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg UniversitySearch for more papers by this authorJochen Herrmann MD, Jochen Herrmann MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg UniversitySearch for more papers by this authorKatrin Geth MD, Katrin Geth MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg UniversitySearch for more papers by this authorRudolf Korinthenberg MD, Rudolf Korinthenberg MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg UniversitySearch for more papers by this authorSteffen Berweck MD, Steffen Berweck MD Department of Pediatric Neurology and Developmental Medicine, Dr von Hauner's Children's Hospital, University of Munich, Germany.Search for more papers by this authorFlorian Heinen MD, Florian Heinen MD Department of Pediatric Neurology and Developmental Medicine, Dr von Hauner's Children's Hospital, University of Munich, Germany.Search for more papers by this authorVolker Mall MD, Volker Mall MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg UniversitySearch for more papers by this author Michaela Linder-Lucht MD, Corresponding Author Michaela Linder-Lucht MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg University *Correspondence to: [email protected]Search for more papers by this authorJanbernd Kirschner MD, Janbernd Kirschner MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg UniversitySearch for more papers by this authorJochen Herrmann MD, Jochen Herrmann MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg UniversitySearch for more papers by this authorKatrin Geth MD, Katrin Geth MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg UniversitySearch for more papers by this authorRudolf Korinthenberg MD, Rudolf Korinthenberg MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg UniversitySearch for more papers by this authorSteffen Berweck MD, Steffen Berweck MD Department of Pediatric Neurology and Developmental Medicine, Dr von Hauner's Children's Hospital, University of Munich, Germany.Search for more papers by this authorFlorian Heinen MD, Florian Heinen MD Department of Pediatric Neurology and Developmental Medicine, Dr von Hauner's Children's Hospital, University of Munich, Germany.Search for more papers by this authorVolker Mall MD, Volker Mall MD Department of Neuropediatrics and Muscular Disorders, Children's University Hospital, Freiburg UniversitySearch for more papers by this author First published: 02 March 2007 https://doi.org/10.1017/S0012162206000697Citations: 17AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Berweck S., Heinen F. (2004) Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord 19 (Suppl 8): S162– S167. 2 Jefferson RJ. (2004) Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol 46: 491– 499. 3 Brashear A., Bergan K., Wojcieszek J., Siemers ER., Ambrosius W. (2000) Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 15: 150– 153. 4 Calace P., Cortese G., Piscopo R., Della Volpe G., Gagliardi V., Magli A., De Berardinis T. (2003) Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol 13: 331– 336. 5 Defazio G., Abbruzzese G., Girlanda P., Vacca L., Curra A., De Salvia R., Marchese R., Raineri R., Roselli F., Livrea P., Berardelli A. (2002) Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 59: 418– 420. 6 Hsiung GY., Das SK., Ranawaya R., Lafontaine AL., Suchowersky O. (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17: 1288– 1293. 7 Palisano RJ. (1993) Validity of goal attainment scaling in infants with motor delays. Phys Ther 73: 651– 658. 8 Herrmann J., Geth K., Mall V., Bigalke H., Schulte-Mönting J., Linder M., Kirschner J., Berweck S., Korinthenberg R., Heinen F., Fietzek UM. (2004) Clinical impact of antibody formation to botulinum toxinAin children. Ann Neurol 55: 732– 735. 9 Jankovic J., Vuong KD., Ahsan J. (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60: 1186– 1188. Citing Literature Volume48, Issue4April 2006Pages 319-320 ReferencesRelatedInformation